Global Phenylpropanolamine (PPA) Market, By Indication (Colds, Hay Fever, Upper Respiratory Allergies, Sinusitis, and Others), Chemistry (D- and L-Norephedrine and D- and L-Norpseudoephedrine), Application (Human and Veterinary), Drug Type (Over the Counter and Prescription), Population Type (Children and Adults), Dosage Form (Solid Dosage Form, Liquid Dosage Form, and Others), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) – Industry Trends and Forecast to 2030.
Phenylpropanolamine (PPA) Market Analysis and Size
PPA or phenylpropanolamine, is a synthetic substance that suppresses hunger and functions as a decongestant. The phenylpropanolamine (PPA) market will start to take off over the projection above period due to several changes brought on by the rising disposable income of customers in emerging economies and the use of this medicine in various combinations.
Data Bridge Market Research analyses that the phenylpropanolamine market is expected to undergo a CAGR of 5.8% during the forecast period of 2023 to 2030. “Over the Counter” dominates the drug type segment of the phenylpropanolamine market owing to the increasing prevalence of drug usage. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Phenylpropanolamine (PPA) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Indication (Colds, Hay Fever, Upper Respiratory Allergies, Sinusitis, and Others), Chemistry (D- and L-Norephedrine and D- and L-Norpseudoephedrine), Application (Human and Veterinary), Drug Type (Over the Counter and Prescription), Population Type (Children and Adults), Dosage Form (Solid Dosage Form, Liquid Dosage Form, and Others), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa.
|
|
Market Players Covered
|
|
|
Market Opportunities
|
|
Market Definition
PPA, or phenylpropanolamine, is a synthetic substance that suppresses hunger and functions as a decongestant. It is a member of the group of medications known as sympathomimetic amines, which imitate the actions of the sympathetic nervous system. PPA was frequently found as a component in over-the-counter drugs for sinusitis, nasal congestion, and weight loss.
Phenylpropanolamine (PPA) Market Dynamics
Drivers
- Increasing awareness regarding phenylpropanolamine
For proper patient care, educating healthcare personnel about the safety issues with PPA is essential. The distribution of up-to-date knowledge regarding PPA and its alternatives is aided by clinical guidelines, continuing medical education programs, and conversations within the medical community. To encourage safe medicine usage, it is essential to inform customers about the dangers and possible adverse effects of PPA. Healthcare experts' knowledge, product labels, and consumer awareness initiatives can all assist people in making educated healthcare decisions. Thus increasing awareness regarding phenylpropanolamine is acting as a driver for market growth.
- Increasing research activities
Pharmaceutical firms or researchers may have the chance to investigate the creation of decongestants or appetite suppressants that are safer and more potent. There is still a market for these goods; innovation in this field could allay PPA's safety worries.
- Rising technological advancements
Developments can aid the development of new drugs in computational modeling, molecular biology, and high-throughput screening. These developments may eventually lead to the discovery of decongestants or appetite suppressants that are safer and more potent than PPA. Henceforth, rising technological advancements and innovations across the globe demonstrate the market's future growth.
Opportunities
- Rising usage of combination products
In medicine, phenylpropanolamine was frequently used in conjunction with other active substances. It may be possible to create medicines addressing several symptoms or health issues, for example, by combining decongestant characteristics with other therapeutic advantages. This might satisfy changing consumer preferences and needs. This creates a major opportunity for the market.
- Rising healthcare expenditure
The expense of money a country uses on its healthcare and its growth rate over time is inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the organization of the health system. Healthcare expenditure has increased across developed countries and emerging economies as people's disposable income rises. Hence, colossal healthcare expenditure is a favorable factor for market growth.
- Increasing demand for personalized medicine
Personalized medicine has been made possible by developing technology like genetic testing, biomarker identification, and data analytics. This method customizes medical care to each person's specific traits and requirements. Although not directly connected to PPA, personalized medicine may influence the creation of upcoming drugs and treatment plans. These affirmative factors enhance the opportunity for market growth.
Challenges/ Restraints
- Regulatory guidelines
Governmental constraints on regulatory freedom have greatly impacted the world PPA market. Many nations have outright outlawed PPA use or imposed onerous restrictions on its sale and distribution. These regulatory efforts restrict the use of PPA-based goods by reducing their availability and market potential. Thus, regulatory guidelines for phenylpropanolamine may hamper the market's future growth.
- Safety concerns
Safety issues related to its use have been the main barrier to the market for PPA. It has been related in studies to a higher risk of stroke, particularly in women. As a result, regulatory bodies in numerous nations have taken steps to limit or forbid the sale of drugs that contain PPA. The demand for PPA has decreased, and consumers are switching to other decongestants and appetite suppressants due to safety concerns. Thus, safety concerns for phenylpropanolamine may hamper the market growth.
- Availability of alternatives
In addition, the market expansion has been constrained by the advent of safer substitutes. Pharmacies and academics have created and marketed substitute decongestants and appetite suppressants with superior safety profiles as worries about PPA's safety have grown. There is now less demand for PPA because more patients and healthcare professionals are switching to these safer substitutes.
- The cost associated with biomarker discovery
Consumer choices and awareness significantly shape the market dynamics. The difficulty is raising customer awareness of the safety issues around PPA and encouraging safer substitutes. Effective marketing tactics and awareness-raising efforts are needed to adapt to changing customer preferences and raise public awareness. Thus, changing consumer preferences and awareness regarding phenylpropanolamine may challenge the market's growth.
This phenylpropanolamine (PPA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the phenylpropanolamine (PPA) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Phenylpropanolamine (PPA) Market Scope
The phenylpropanolamine (PPA) market is segmented on the basis of indication, chemistry, application, drug type, population type, dosage form, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Indication
- Colds
- Hay fever
- Upper respiratory allergies
- Sinusitis
- Others
Application
- Human
- Veterinary
Drug Type
- Over the Counter
- Prescription
Population Type
- Children
- Adults
Dosage Form
- Solid dosage form
- Tablets
- Capsules
- Liquid dosage form
- Others
End User
- Hospitals
- Specialty Clinics
- Home healthcare
- Others
Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Others
Phenylpropanolamine (PPA) Market Regional Analysis/Insights
The phenylpropanolamine (PPA) market is analysed and market size insights and trends are provided by indication, chemistry, application, drug type, population type, dosage form, end user and distribution channel as referenced above.
The countries covered in the phenylpropanolamine (PPA) market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa.
Asia-Pacific governs the market industry due to the drug's availability in OTC and prescription and rising disposable income. At the same time, Europe is anticipated to expand at the leading germination pace from 2023 to 2030 due to the presence of an isomeric form of this drug in the European market.
The country section of the phenylpropanolamine (PPA) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The phenylpropanolamine (PPA) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Phenylpropanolamine (PPA) Market Share Analysis
The phenylpropanolamine (PPA) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to phenylpropanolamine (PPA) market.
Some of the major players operating in the phenylpropanolamine (PPA) market are:
- RIEMSER Pharma GmbH (Germany)
- Abbott (U.S.)
- Helicon (Canada)
- EIPICO (Egypt)
- Schazoo Pharmaceuticals Pvt. Ltd (Pakistan)
- GlaxoSmithKline plc (U.K.)
- Roemmers SAICF (Argentina)
- Taj Pharmaceuticals Ltd. (India)
- Cipla Inc. (India)
- Medline Industries, Inc. (U.S.)
- Sanofi (France)
- Tempo Scan Pacific Tbk Carinopharm (Indonesia)
- IBL HealthCare (India)
- PT. Gracia Pharmindo (Indonesia)
SKU-